Postoperative RT linked to improved survival after chemoimmunotherapy and esophagectomy

In 71 matched pairs with esophageal squamous cell carcinoma, postoperative RT was associated with 91.0% versus 75.5% two-year overall survival.

KEY POINTS

  • This retrospective single-center study from Shandong Cancer Hospital, China, analyzed 336 patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoimmunotherapy followed by R0 esophagectomy between February 2021 and November 2024. Postoperatively, 93 patients received radiotherapy plus systemic therapy, while 243 received systemic therapy alone. Propensity score matching generated 71 pairs (142 patients), with a median follow-up of 26 months in the overall cohort.
  • All patients received two to four cycles of neoadjuvant chemotherapy plus immunotherapy before surgery, predominantly taxane/platinum-based regimens combined with PD-1/PD-L1 inhibitors. Postoperative systemic treatment varied according to tolerance and recovery. PORT used IMRT targeting selected supraclavicular, mediastinal, and regional nodal areas with 5–8 mm PTV margins; the primary tumor bed was not routinely included after R0 resection. Among PORT recipients, 76.3% received radiation without overlapping systemic treatment, while 23.7% received concurrent treatment.
  • Postoperative radiotherapy was associated with significantly improved disease-free survival after matching. Two-year DFS was 74.2% with PORT versus 50.1% with systemic therapy alone, an absolute difference of 24.1 percentage points (HR 0.525, 95% CI 0.303–0.911; p=0.018). Median DFS was not reached in the PORT group compared with 25.0 months in the control group. In the unmatched cohort, however, PORT was not significantly associated with DFS (HR 0.921; p=0.707).
  • Overall survival also favored PORT in the propensity-matched population. Two-year OS was 91.0% versus 75.5%, an absolute difference of 15.5 percentage points (HR 0.409, 95% CI 0.181–0.925; p=0.026). Median OS was not reached in either matched group. In multivariable analysis of the original cohort, PORT remained associated with improved DFS (adjusted HR 0.45, 95% CI 0.28–0.74; p=0.002) and OS (adjusted HR 0.32, 95% CI 0.15–0.68; p=0.003), although the unadjusted comparisons showed no significant survival differences.
  • Exploratory subgroup analyses suggested stronger associations in patients with residual high-risk disease. Among patients with ypN-positive disease, PORT was associated with improved DFS (HR 0.49, 95% CI 0.26–0.92; p=0.027), with a similar result for ypStage III–IV disease (HR 0.49; p=0.027). Vascular tumor embolism, poor pathological response, and other adverse features were also investigated. However, subgroup sizes were limited, and no validated treatment-interaction analysis established which patients derive a differential benefit from PORT.
  • Recurrence patterns differed numerically, but the distribution was not significantly different. Among patients who developed progression, locoregional recurrence accounted for 32.1% (9/28) of failures in the PORT group versus 48.1% (39/81) in the systemic-therapy group. Distant metastasis accounted for 46.4% versus 24.7% of reported failures, respectively. These percentages describe the distribution among patients with recurrence, not cumulative recurrence incidence in all treated patients, and the overall difference in failure patterns was not statistically significant (p=0.214).
  • Severe toxicity was predominantly hematologic, but long-term safety remains uncertain. Among 93 PORT recipients, 17 (18.3%) experienced grade ≥3 treatment-related adverse events, including grade ≥3 leukopenia and neutropenia in 7.5% each. Radiation esophagitis occurred in 38.7%, including one grade 3 event (1.1%), with no reported grade ≥4 radiation-related toxicity. Interpretation is limited by heterogeneous systemic regimens, nonrandom PORT selection, and potential immortal-time bias: PORT began a median 85 days after surgery, requiring patients to remain eligible for treatment. No time-dependent or landmark analysis was performed to fully address this bias.

CLINICAL TAKEAWAY

Postoperative radiotherapy was associated with improved disease-free and overall survival after neoadjuvant chemoimmunotherapy and R0 esophagectomy for locally advanced esophageal squamous cell carcinoma, particularly in patients with residual nodal or advanced pathological disease. These findings support further investigation of PORT as a postoperative intensification strategy, but residual confounding, immortal-time bias, and limited follow-up prevent establishing a causal survival benefit. Prospective studies are needed to define which patients benefit from adding PORT to contemporary postoperative systemic treatment.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction